Clinical and subclinical acute kidney injury in multidrug-resistant septic patients treated with colistimethate sodium: Incidence and clinical outcomes.

Theerachai ThammathiwatKhajohn TiranathanagulNattachai SrisawatPaweena SusantitaphongKearkiat PraditpornsilpaSomchai Eiam-Ong

Published in: Nephrology (Carlton, Vic.) (2019)

The incidence of subclinical AKI in MDR septic patients before CMS treatment was extremely high. The baseline uL-FABP provided the best predictive capacity of clinical AKI. The causes of clinical AKI might include the persistence of sepsis process, subclinical AKI and CMS nephrotoxicity. Proper management of subclinical AKI patients before CMS initiation should be concerned to prevent further renal damage and improve patient and renal outcomes.

Keyphrases

acute kidney injury
multidrug resistant
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
risk factors
intensive care unit
escherichia coli
drug resistant
patient reported outcomes
binding protein
skeletal muscle